<DOC>
	<DOCNO>NCT00772577</DOCNO>
	<brief_summary>Study Evaluate Efficacy Safety Aliskiren Hydrochlorothiazide ( HCTZ ) v Ramipril Obese patient ( BMI ≥ 30 ) Stage 2 Hypertension</brief_summary>
	<brief_title>Study Efficacy Safety Aliskiren HCTZ v Ramipril Obese Patients ( BMI ≥ 30 ) With Stage 2 Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Patients eligible able participate study , give write informed consent assessment perform . Male female outpatient , 18 year age old . Patients Stage 2 hypertension . Patients must MSSBP ≥ 160 mmHg &lt; 200 mmHg Study Visit 5 ( randomization ) . Patients must BMI ≥ 30 kg/m2 ≤ 45 kg/m2 . Office blood pressure measure cuff ( MSDBP ≥ 110 mmHg and/or MSSBP ≥ 200 mmHg ) visit . Use investigational drug within 30 day enrollment , 5 halflives , ever longer . Use aliskiren and/or fix dose combination aliskiren HCTZ participation clinical trial aliskiren and/or aliskiren HCTZ treatment within 30 day Visit 1 . History hypersensitivity study drug drug belong therapeutic class ( ACE inhibitor renin inhibitor ) study drug . History evidence secondary form hypertension . Refractory hypertension , define , unresponsive triple drug therapy maximum dose drug , one must diuretic , blood pressure goal ( 140/90 mmHg ) . Therapy fix dose combination two active substance represent two drug . Patients 4 antihypertensive medication . Long QT syndrome QTc &gt; 450 msec male &gt; 470 msec female screen . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Hypertension , Obese , aliskiren , hydrochlorothiazide , systolic blood pressure , diastolic blood pressure , ramipril , stage 2</keyword>
</DOC>